Alkermes plc. Proceeds from Sale and Maturity of Marketable Securities
Alkermes plc. (ALKS) reported Proceeds from Sale and Maturity of Marketable Securities of $62.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-07-28
- Alkermes plc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $20.09M, a 75.38% decline year-over-year.
- Alkermes plc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $42.61M, a 62.46% decline year-over-year.
- Alkermes plc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $377.11M, a 341.06% increase year-over-year.
- Alkermes plc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $125.31M, a 45.98% increase year-over-year.
- Alkermes plc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $697.49M, a 124.79% increase from fiscal 2024.
- Alkermes plc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $310.29M, a 12.72% decline from fiscal 2023.
- Alkermes plc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $355.52M, a 26.24% increase from fiscal 2022.
- Alkermes plc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $281.63M, a 4.54% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $62.69M 10-Q · filed 2026-07-28 | $439.80M derived: sum of 3 quarters · filed 2026-07-28 | $565.11M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $42.61M 10-Q · filed 2026-05-05 | $419.72M derived: sum of 2 quarters · filed 2026-05-05 | $545.02M derived: sum of 3 quarters · filed 2026-05-05 | $626.61M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $377.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $502.41M derived: sum of 2 quarters · filed 2026-02-25 | $584.00M derived: sum of 3 quarters · filed 2026-07-28 | $697.49M 10-K · filed 2026-02-25 |
| 2025-09-30 | $125.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $206.90M derived: sum of 2 quarters · filed 2026-07-28 | $320.38M 10-Q · filed 2025-10-28 | $405.88M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $81.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $195.08M 10-Q · filed 2026-07-28 | $280.58M derived: sum of 3 quarters · filed 2026-07-28 | $366.42M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $113.49M 10-Q · filed 2026-05-05 | $198.99M derived: sum of 2 quarters · filed 2026-05-05 | $284.83M derived: sum of 3 quarters · filed 2026-05-05 | $341.29M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $85.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $171.34M derived: sum of 2 quarters · filed 2026-02-25 | $227.80M derived: sum of 3 quarters · filed 2026-02-25 | $310.29M 10-K · filed 2026-02-25 |
| 2024-09-30 | $85.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $142.30M derived: sum of 2 quarters · filed 2025-10-28 | $224.79M 10-Q · filed 2025-10-28 | $288.36M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $56.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $138.95M 10-Q · filed 2025-07-29 | $202.53M derived: sum of 3 quarters · filed 2026-02-25 | $253.93M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $82.49M 10-Q · filed 2025-05-01 | $146.07M derived: sum of 2 quarters · filed 2026-02-25 | $197.47M derived: sum of 3 quarters · filed 2026-02-25 | $334.40M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $63.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $114.98M derived: sum of 2 quarters · filed 2026-02-25 | $251.91M derived: sum of 3 quarters · filed 2026-02-25 | $355.52M 10-K · filed 2026-02-25 |
| 2023-09-30 | $51.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24 | $188.34M derived: sum of 2 quarters · filed 2024-10-24 | $291.94M 10-Q · filed 2024-10-24 | $382.58M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $136.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | $240.54M 10-Q · filed 2024-07-24 | $331.18M derived: sum of 3 quarters · filed 2025-02-12 | $412.25M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $103.61M 10-Q · filed 2024-05-01 | $194.24M derived: sum of 2 quarters · filed 2025-02-12 | $275.31M derived: sum of 3 quarters · filed 2025-02-12 | $324.46M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $90.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $171.70M derived: sum of 2 quarters · filed 2025-02-12 | $220.85M derived: sum of 3 quarters · filed 2025-02-12 | $281.63M 10-K · filed 2025-02-12 |
| 2022-09-30 | $81.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | $130.22M derived: sum of 2 quarters · filed 2023-10-25 | $190.99M 10-Q · filed 2023-10-25 | $246.78M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $49.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | $109.92M 10-Q · filed 2023-07-26 | $165.71M derived: sum of 3 quarters · filed 2024-02-21 | $229.44M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $60.78M 10-Q · filed 2023-04-26 | $116.56M derived: sum of 2 quarters · filed 2024-02-21 | $180.29M derived: sum of 3 quarters · filed 2024-02-21 | $269.60M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $55.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $119.51M derived: sum of 2 quarters · filed 2024-02-21 | $208.82M derived: sum of 3 quarters · filed 2024-02-21 | $295.01M 10-K · filed 2024-02-21 |
| 2021-09-30 | $63.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $153.03M derived: sum of 2 quarters · filed 2022-11-02 | $239.23M 10-Q · filed 2022-11-02 | $286.14M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | $89.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $175.50M 10-Q · filed 2022-07-27 | $222.41M derived: sum of 3 quarters · filed 2023-02-16 | $280.64M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | $86.19M 10-Q · filed 2022-04-27 | $133.10M derived: sum of 2 quarters · filed 2023-02-16 | $191.34M derived: sum of 3 quarters · filed 2023-02-16 | $274.69M derived: sum of 4 quarters · filed 2023-02-16 |
| 2020-12-31 | $46.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $105.14M derived: sum of 2 quarters · filed 2023-02-16 | $188.50M derived: sum of 3 quarters · filed 2023-02-16 | $253.00M 10-K · filed 2023-02-16 |
| 2020-09-30 | $58.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $141.59M derived: sum of 2 quarters · filed 2021-10-27 | $206.09M 10-Q · filed 2021-10-27 | $281.23M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $83.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $147.86M 10-Q · filed 2021-07-28 | $223.00M derived: sum of 3 quarters · filed 2022-02-16 | $293.36M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $64.50M 10-Q · filed 2021-04-28 | $139.64M derived: sum of 2 quarters · filed 2022-02-16 | $210.00M derived: sum of 3 quarters · filed 2022-02-16 | $233.12M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $75.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $145.50M derived: sum of 2 quarters · filed 2022-02-16 | $168.62M derived: sum of 3 quarters · filed 2022-02-16 | $224.60M 10-K · filed 2022-02-16 |
| 2019-09-30 | $70.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $93.48M derived: sum of 2 quarters · filed 2020-10-29 | $149.46M 10-Q · filed 2020-10-29 | $249.29M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $23.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $79.10M 10-Q · filed 2020-07-29 | $178.94M derived: sum of 3 quarters · filed 2021-02-11 | $390.46M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $55.98M 10-Q · filed 2020-04-29 | $155.81M derived: sum of 2 quarters · filed 2021-02-11 | $367.33M derived: sum of 3 quarters · filed 2021-02-11 | $420.93M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $99.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $311.36M derived: sum of 2 quarters · filed 2021-02-11 | $364.96M derived: sum of 3 quarters · filed 2021-02-11 | $444.46M 10-K · filed 2021-02-11 |
| 2018-09-30 | $211.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-23 | $265.12M derived: sum of 2 quarters · filed 2019-10-23 | $344.62M 10-Q · filed 2019-10-23 | $490.63M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $53.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $133.10M 10-Q · filed 2019-07-25 | $279.10M derived: sum of 3 quarters · filed 2020-02-13 | $406.95M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $79.50M 10-Q · filed 2019-04-25 | $225.50M derived: sum of 2 quarters · filed 2020-02-13 | $353.35M derived: sum of 3 quarters · filed 2020-02-13 | $488.99M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $146.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $273.85M derived: sum of 2 quarters · filed 2020-02-13 | $409.49M derived: sum of 3 quarters · filed 2020-02-13 | $464.49M 10-K · filed 2020-02-13 |
| 2017-09-30 | $127.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $263.49M derived: sum of 2 quarters · filed 2018-10-23 | $318.49M 10-Q · filed 2018-10-23 | $385.78M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-06-30 | $135.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $190.64M 10-Q · filed 2018-07-26 | $257.93M derived: sum of 3 quarters · filed 2019-02-15 | $443.49M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-03-31 | $55.00M 10-Q · filed 2018-04-26 | $122.28M derived: sum of 2 quarters · filed 2019-02-15 | $307.85M derived: sum of 3 quarters · filed 2019-02-15 | $457.58M derived: sum of 4 quarters · filed 2019-02-15 |
| 2016-12-31 | $67.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $252.85M derived: sum of 2 quarters · filed 2019-02-15 | $402.58M derived: sum of 3 quarters · filed 2019-02-15 | $560.80M 10-K · filed 2019-02-15 |
| 2016-09-30 | $185.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $335.30M derived: sum of 2 quarters · filed 2017-10-26 | $493.52M 10-Q · filed 2017-10-26 | $625.92M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $149.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $307.95M 10-Q · filed 2017-07-27 | $440.36M derived: sum of 3 quarters · filed 2018-02-16 | $563.38M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $158.22M 10-Q · filed 2017-04-27 | $290.63M derived: sum of 2 quarters · filed 2018-02-16 | $413.65M derived: sum of 3 quarters · filed 2018-02-16 | $526.87M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $132.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $255.43M derived: sum of 2 quarters · filed 2018-02-16 | $368.65M derived: sum of 3 quarters · filed 2018-02-16 | $467.57M 10-K · filed 2018-02-16 |
| 2015-09-30 | $123.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $236.24M derived: sum of 2 quarters · filed 2016-11-02 | $335.17M 10-Q · filed 2016-11-02 | $429.78M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $113.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $212.14M 10-Q · filed 2016-07-28 | $306.76M derived: sum of 3 quarters · filed 2017-02-17 | $368.85M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $98.93M 10-Q · filed 2016-04-28 | $193.54M derived: sum of 2 quarters · filed 2017-02-17 | $255.63M derived: sum of 3 quarters · filed 2017-02-17 | $355.58M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $94.61M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $156.71M derived: sum of 2 quarters · filed 2017-02-17 | $256.65M derived: sum of 3 quarters · filed 2017-02-17 | $341.15M 10-K · filed 2017-02-17 |
| 2014-09-30 | $62.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $162.04M derived: sum of 2 quarters · filed 2015-10-29 | $246.54M 10-Q · filed 2015-10-29 | $280.61M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $99.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $184.45M 10-Q · filed 2015-07-30 | $218.52M derived: sum of 3 quarters · filed 2016-02-25 | $243.52M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $84.50M 10-Q · filed 2015-04-30 | $118.57M derived: sum of 2 quarters · filed 2016-02-25 | $143.57M derived: sum of 3 quarters · filed 2016-02-25 | $174.97M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $34.07M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | $59.07M derived: sum of 2 quarters · filed 2016-02-25 | $90.47M 10-K · filed 2016-02-25 | $129.22M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-09-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $56.40M 10-Q · filed 2013-10-31 | $95.15M 10-Q · filed 2014-10-29 | $129.94M derived: sum of 4 quarters · filed 2014-04-30 |
| 2013-06-30 | $31.40M 10-Q · filed 2013-07-25 | $70.15M 10-Q · filed 2014-07-31 | $104.94M derived: sum of 3 quarters · filed 2014-04-30 | $233.65M derived: sum of 4 quarters · filed 2014-04-30 |
| 2013-03-31 | $38.75M 10-Q · filed 2014-04-30 | $73.55M derived: sum of 2 quarters · filed 2014-04-30 | $202.25M derived: sum of 3 quarters · filed 2014-04-30 | $258.94M 10-K · filed 2015-02-24 |
| 2012-12-31 | $34.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $163.50M derived: sum of 2 quarters · filed 2013-10-31 | $220.19M 10-Q · filed 2013-01-31 | $275.61M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-09-30 | $128.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $185.39M 10-Q · filed 2013-10-31 | $240.82M derived: sum of 3 quarters · filed 2014-02-27 | $268.06M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $56.69M 10-Q · filed 2013-07-25 | $112.11M derived: sum of 2 quarters · filed 2014-02-27 | $139.35M derived: sum of 3 quarters · filed 2014-02-27 | $304.47M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $55.42M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $82.67M derived: sum of 2 quarters · filed 2014-02-27 | $247.79M derived: sum of 3 quarters · filed 2014-02-27 | $323.03M 10-KT · filed 2014-02-27 |
| 2011-12-31 | $27.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $192.36M derived: sum of 2 quarters · filed 2013-01-31 | $267.60M 10-Q · filed 2013-01-31 | $303.57M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-09-30 | $165.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-01 | $240.36M 10-Q · filed 2012-11-01 | $276.33M derived: sum of 3 quarters · filed 2013-05-23 | $349.44M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-06-30 | $75.24M 10-Q · filed 2012-07-26 | $111.20M derived: sum of 2 quarters · filed 2013-05-23 | $184.31M derived: sum of 3 quarters · filed 2013-05-23 | |
| 2011-03-31 | $35.97M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $109.07M derived: sum of 2 quarters · filed 2013-05-23 | $385.51M 10-K · filed 2013-05-23 | |
| 2010-12-31 | $73.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | $349.55M 10-Q · filed 2012-02-02 | ||
| 2010-09-30 | $276.44M 10-Q · filed 2011-11-03 | |||
| 2010-03-31 | $516.93M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |